About Protalex (OTCMKTS:PRTX)
Protalex, Inc. is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company's lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The Company's pre-clinical studies demonstrated that low doses of PRTX-100 have potent therapeutic effects in certain models of immune-mediated inflammatory diseases. Both the PRTX-100-103 and the PRTX-100-104 studies demonstrated that PRTX-100 is safe and well tolerated at all dose levels.
Industry, Sector and Symbol:
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:PRTX
- Previous Symbol: NASDAQ:PRTX
- CUSIP: N/A
- Web: www.protalex.com
- Debt-to-Equity Ratio: -1.00%
- Current Ratio: 0.85%
- Quick Ratio: 0.85%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: ($0.76) per share
- Price / Book: -1.45
- Trailing EPS: ($0.16)
- Net Income: $-4,560,000.00
- Return on Assets: -823.75%
- Employees: 2
- Outstanding Shares: 28,770,000
Frequently Asked Questions for Protalex (OTCMKTS:PRTX)
What is Protalex's stock symbol?
Protalex trades on the OTCMKTS under the ticker symbol "PRTX."
How were Protalex's earnings last quarter?
Protalex, Inc. (OTCMKTS:PRTX) posted its earnings results on Wednesday, October, 11th. The company reported ($0.04) earnings per share (EPS) for the quarter. View Protalex's Earnings History.
When will Protalex make its next earnings announcement?
Who are some of Protalex's key competitors?
Some companies that are related to Protalex include Catasys (CATS), IntelGenx Technologies Corp. (IGXT), Presbia PLC (LENS), Digirad Corporation (DRAD), Ocera Therapeutics (OCRX), Proteostasis Therapeutics (PTI), OmniComm Systems (OMCM), Biosig Technologies (BSGM), ReShape Lifesciences (RSLS), Azurrx Biopharm (AZRX), Celsion Corporation (CLSN), Intellipharmaceutics International (IPCI), Streamline Health Solutions (STRM), Trimel Pharmaceuticals Corp. (TRLPF), RegeneRx Biopharmaceuticals (RGRX), Tonix Pharmaceuticals Holding Corp. (TNXP), ReWalk Robotics Ltd (RWLK) and Kitov Pharmaceuticals Holdings (KTOV).
Who are Protalex's key executives?
Protalex's management team includes the folowing people:
- Arnold P. Kling, President, Director
- Kirk M. Warshaw, Chief Financial Officer, Secretary, Director
- Marco M. Elser, Independent Director
How do I buy Protalex stock?
Shares of Protalex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalex's stock price today?
One share of Protalex stock can currently be purchased for approximately $1.10.
How big of a company is Protalex?
Protalex has a market capitalization of $31.64 million. The company earns $-4,560,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Protalex employs 2 workers across the globe.
How can I contact Protalex?
Protalex's mailing address is 131 Columbia Tpke Ste 1A, FLORHAM PARK, NJ 07932-2181, United States. The company can be reached via phone at +1-215-8629720 or via email at [email protected]
MarketBeat Community Rating for Protalex (OTCMKTS PRTX)MarketBeat's community ratings are surveys of what our community members think about Protalex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Protalex (OTCMKTS:PRTX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Protalex (OTCMKTS:PRTX)
Analysts' Ratings History for Protalex (OTCMKTS:PRTX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Protalex (OTCMKTS:PRTX)
Earnings History by Quarter for Protalex (OTCMKTS PRTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/11/2018|| || || || || || || || |
Earnings Estimates for Protalex (OTCMKTS:PRTX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Protalex (OTCMKTS:PRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Protalex (OTCMKTS PRTX)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Protalex (OTCMKTS PRTX)
Protalex (OTCMKTS PRTX) Chart for Tuesday, November, 21, 2017